<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157751</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0204</org_study_id>
    <secondary_id>2019-002946-19</secondary_id>
    <nct_id>NCT04157751</nct_id>
  </id_info>
  <brief_title>A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure</brief_title>
  <official_title>A Multicentre, Randomised, Double-blind, 90-day Superiority Trial to Evaluate the Effect on Clinical Benefit, Safety and Tolerability of Once Daily Oral EMPagliflozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for acUte Heart faiLure (de Novo or Decompensated Chronic HF) Who Have Been StabilisEd (EMPULSE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess whether in-hospital administration of
      empagliflozin results in improvements in heart failure (HF)-related clinical events and
      patient-reported outcomes (death, heart failure events (HFE) and Kansas City Cardiomyopathy
      Questionnaire - Total Symptom Score (KCCQ-TSS) as a measure of health status (symptoms)) in
      patients hospitalised for acute heart failure (de novo or decompensated chronic HF) and after
      initial stabilisation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">July 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The clinical benefit, a composite of death, number of HFE (including HHFs), urgent heart failure visits and unplanned outpatient visits), time to first HFE and change from baseline KCCQ-TSS after 90 days of treatment assessed by the win ratio.</measure>
    <time_frame>Baseline and after 90 days of treatment</time_frame>
    <description>Hospitalisations for Heart Failure (HHF) Heart Failure Event (HFE) Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in KCCQ-TSS of ≥ 10 points</measure>
    <time_frame>After 90 days of treatment</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in KCCQ-TSS after 90 days of treatment</measure>
    <time_frame>Baseline and after 90 days of treatment</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire - Total Symptom Score(KCCQ-TSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log-transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) level over 30 days of treatment (area under the curve (AUC))</measure>
    <time_frame>Baseline and after 30 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital from study drug initiation until 30 days after initial hospital discharge</measure>
    <time_frame>30 days after initial hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital from study drug initiation until 90 days after randomisation</measure>
    <time_frame>90 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of CV death or HFE until end of trial visit</measure>
    <time_frame>Up to day 97</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of HHF until 30 days after initial hospital discharge</measure>
    <time_frame>30 days after initial hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of chronic dialysis or renal transplant or sustained1 reduction of ≥40% eGFR Chronic Kidney Disease Epidemiology Collaboration Equation ((CKD-EPI)cr)</measure>
    <time_frame>Up to day 97</time_frame>
    <description>or
sustained eGFR (CKD-EPI)cr &lt;15 mL/min/1.73 m2 for patients with baseline eGFR ≥30 mL/min/1.73 m2
sustained eGFR (CKD-EPI)cr &lt;10 mL/min/1.73 m2 for patients with baseline eGFR &lt;30 mL/min/1.73 m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic effect as assessed by weight loss per mean daily loop diuretic dose after 15 days of treatment</measure>
    <time_frame>After 15 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic effect as assessed by weight loss per mean daily loop diuretic dose after 30 days of treatment</measure>
    <time_frame>After 30 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Empagliflozin</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently hospitalised for the primary diagnosis of acute heart failure (de novo or
             decompensated chronic HF), regardless of ejection fraction (EF). Patients with a
             diagnosis of hospitalized heart failure must have HF symptoms at the time of hospital
             admission

          -  Evidence of left ventricular ejection fraction (LVEF, either reduced or preserved EF)
             as per local reading preferably measured during current hospitalisation or in the 12
             months prior to randomisation

          -  Patients must be randomised after at least 24 hours and no later than 5 days after
             admission, as early as possible after stabilization and while still in hospital

          -  Patients must fulfil the following stabilisation criteria (while in the hospital):

               -  SBP ≥100mm Hg and no symptoms of hypotension in the preceding 6 hours,

               -  no increase in i.v. diuretic dose for 6 hours prior to randomisation,

               -  no i.v. vasodilators including nitrates within the last 6 hours prior to
                  randomisation

               -  no i.v. inotropic drugs for 24 hours prior to randomisation.

          -  Elevated NT-proBNP ≥ 1600pg/mL or BNP ≥400 pg/mL according to the local lab, for
             patients without atrial fibrillation (AF); or elevated NT-proBNP ≥ 2400pg/mL or BNP
             ≥600 pg/mL for patients with AF, measured during the current hospitalization or in the
             72 hours prior to hospital admission,. For patients treated with an angiotensin
             receptor neprilysin inhibitor (ARNI) in the previous 4 weeks prior to randomisation,
             only NT-proBNP values should be used

          -  HF episode leading to hospitalisation must have been treated with a minimum single
             dose of 40 mg of i.v. furosemide (or equivalent i.v. loop diuretic defined as 20 mg of
             torasemide or 1 mg of bumetanide)

          -  Further Inclusion Criteria Apply

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Current hospitalisation for acute heart failure primarily triggered by pulmonary
             embolism, cerebrovascular accident, or acute myocardial infarction (AMI)

          -  Current hospitalisation for acute heart failure not caused primarily by intravascular
             volume overload;

          -  Below interventions in the past 30 days prior to randomisation or planned during the
             study:

               -  Major cardiac surgery, or TAVI (Transcatheter Aortic Valve Implantation), or PCI,
                  or Mitraclip

               -  All other surgeries that are considered major according to investigator judgement

               -  Implantation of cardiac resynchronisation therapy (CRT) device

               -  cardiac mechanical support implantation

               -  Carotid artery disease revascularisation (stent or surgery)

          -  Acute coronary syndrome / myocardial infarction, stroke or transient ischemic attack
             (TIA) in the past 90 days prior to randomisation

          -  Heart transplant recipient, or listed for heart transplant with expectation to receive
             a transplant during the course of this trial (according to investigator judgement), or
             planned for palliative care for HF, or currently using left ventricular assist device
             (LVAD) or intra-aortic balloon pump (IABP) or any other type of mechanical circulatory
             support, or patients on mechanical ventilation, or patients with planned inotropic
             support in an outpatient setting

          -  Haemodynamically significant (severe) uncorrected primary cardiac valvular disease
             planned for surgery or intervention during the course of the study (note: secondary
             mitral regurgitation or tricuspid regurgitation due to dilated cardiomyopathy is not
             excluded unless planned for surgery or intervention during the course of the study)

          -  Impaired renal function, defined as eGFR &lt; 20 mL/min/1.73 m2 as measured during
             hospitalization (latest local lab measurement before randomisation) or requiring
             dialysis

          -  Type 1 Diabetes Mellitus (T1DM)

          -  History of ketoacidosis, including diabetic ketoacidosis (DKA)

          -  Further Exclusion Criteria Apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology Associates Research Co.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Henderson</last_name>
      <phone>+001 (386) 677-6672</phone>
      <email>cardioresearch.henderson@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Larned</last_name>
      <phone>+001 (954) 229-8400</phone>
      <email>joshua.larned@holy-cross.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Koren</last_name>
      <phone>+001 (904) 423-0010</phone>
      <email>mkoren@encoredocs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Adler</last_name>
      <phone>+001 (309) 672-4670</phone>
      <email>alexander.adler@unitypoint.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willis Knighton Medical Center</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Eaves</last_name>
      <phone>+001 (318) 638-7309</phone>
      <email>weaves.grace@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirkwood Adams</last_name>
      <phone>+001 (919) 843-5226</phone>
      <email>kfa@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmatex Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brabham</last_name>
      <phone>+001 (806) 355-2581</phone>
      <email>pharmatexresearch@ccallp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Cardiac Care - Heart Failure Clinic</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aasim Afzal</last_name>
      <phone>+001 (469) 814-4181</phone>
      <email>Aasim.afzal@bswhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalst - HOSP Onze-Lieve-Vrouw</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert De Raedt</last_name>
      <phone>053/72.44.33</phone>
      <email>herbert.de.raedt@olvz-aalst.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Sarens</last_name>
      <phone>+32(0)52 25 29 50</phone>
      <email>tomsarens@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Janssens</last_name>
      <phone>+32 16 332211</phone>
      <email>stefan.janssens@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liège - HOSP CHR de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Troisfontaines</last_name>
      <phone>+32(0)4 223 86 39</phone>
      <email>Pierre.troisfontaines@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Faculty Hospital, Prague</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Janota</last_name>
      <email>Tomas.Janota@vfn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prag</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaclav Durdil</last_name>
      <phone>+420224434964,+420224434952</phone>
      <email>vdurdil@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetsshospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Søren Vraa</last_name>
      <phone>+45 97664445</phone>
      <email>sov@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Tuxen</last_name>
      <phone>+45 2129 8430</phone>
      <email>Christian.Ditlev.Tuxen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2733</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Schou</last_name>
      <phone>+4538683450</phone>
      <email>morten.schou.04@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Barasa</last_name>
      <phone>+45 38622233</phone>
      <email>anders.barasa@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viborg Regionhospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malene Hollingdal</last_name>
      <phone>+45 78447053</phone>
      <email>malene.hollingdal@midt.rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Leistner</last_name>
      <phone>+49 (30) 450513725</phone>
      <email>David.Leistner@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bremer Institut für Herz- und Kreislaufforschung (BIHKF) am Klinikum Links der Weser</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harm Wienbergen</last_name>
      <phone>+49 (421) 879-4059</phone>
      <email>harm.wienbergen@klinikum-bremen-ldw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus, Essen</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Schueler</last_name>
      <phone>+49 (201) 65056 0</phone>
      <email>r.schueler@contilia.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg, Bad Krozingen GmbH</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Olivier</last_name>
      <email>Christoph.Olivier@universitaets-herzzentrum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen gGmbH, Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Schwimmbeck</last_name>
      <phone>+49 (214) 132 161</phone>
      <email>schwimmbeck@klinikum-lev.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Zeymer</last_name>
      <phone>+49 (621) 5034000</phone>
      <email>ZEYMERU@klilu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingo Eitel</last_name>
      <phone>+49 (451) 500-44501</phone>
      <email>Ingo.Eitel@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Störk</last_name>
      <phone>+49 (931) 20146363</phone>
      <email>stoerk_s@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Debrecen Hospital</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denes Pall</last_name>
      <phone>+36 52 255600</phone>
      <email>pall.denes@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pecs, Invasive Cardiology</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalman Toth</last_name>
      <phone>3672536000,+3672535861</phone>
      <email>toth.kalman@pte.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco METRA</last_name>
      <phone>+39 (030) 3995747</phone>
      <email>metramarco@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale della Val di Chiana Santa Margherita</name>
      <address>
        <city>Cortona (AR)</city>
        <zip>52040</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona D'Orazio</last_name>
      <phone>+39 (0575) 6391</phone>
      <email>simona.dorazio@uslsudest.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Sekishikai Hospital</name>
      <address>
        <city>Saitama, Sayama</city>
        <zip>350-1305</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taro Shibasaki</last_name>
      <phone>+81 4 29536611</phone>
      <email>shibasakitaro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis-Hertogenbosch</name>
      <address>
        <city>'s HERTOGENBOSCH</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Van Eck</last_name>
      <phone>+31 73 699 2403</phone>
      <email>M.v.Eck@jbz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen Apeldoorn</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastazia Jerzewski</last_name>
      <phone>0031 555 818181</phone>
      <email>a.jerzewski@gelre.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TREANT Zorggroep</name>
      <address>
        <city>Emmen</city>
        <zip>7824 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lennaert Kleijn</last_name>
      <phone>0591 69 12 83</phone>
      <email>l.kleijn@treant.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriaan Voors</last_name>
      <phone>+31 503612355</phone>
      <email>a.a.voors@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiden</city>
        <zip>2334 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tjeerd Römer</last_name>
      <phone>0031 715 178178</phone>
      <email>tjromer@alrijne.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bravis ziekenhuis, locatie Roosendaal</name>
      <address>
        <city>Roosendaal</city>
        <zip>4708 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhart Dorman</last_name>
      <phone>0031 887 068000</phone>
      <email>r.dorman@bravis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaco Houtgraaf</last_name>
      <phone>0031 882 505040</phone>
      <email>jhoutgraaf@diakhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus HF</name>
      <address>
        <city>Lørenskog</city>
        <zip>N-1474</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Schirmer</last_name>
      <phone>02900</phone>
      <email>Henrik.schirmer@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Wincenty a Paulo Hosp., Cardiology Dept., Gdynia</name>
      <address>
        <city>Gdynia</city>
        <zip>81348</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Miekus</last_name>
      <phone>+48585552271</phone>
      <email>miekus1@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domingo Pascual Figal</last_name>
      <phone>+34968369500</phone>
      <email>dpascual@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Comin-Colet</last_name>
      <phone>+34933425549</phone>
      <email>Josepcomin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Cobo</last_name>
      <phone>+34911916000</phone>
      <email>martacobomarcos@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Manuel García Pinilla</last_name>
      <phone>+34951032000</phone>
      <email>pinilla@secardiologia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Moises Broggi</name>
      <address>
        <city>Sant Joan Despi</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Román Freixa</last_name>
      <phone>+34935531200</phone>
      <email>roman.freixa@sanitatintegral.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Reyes Dominguez</last_name>
      <phone>+34902105255</phone>
      <email>areyesdom@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Eduardo Núñez</last_name>
      <phone>+34961973520</phone>
      <email>yulnunez@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https:// trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link http://trials.boehringeringelheim. com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

